Auriga's Rating of Protalix BioTherapeutics on 4/30/2012 On April 30, 2012, Auriga updated its outlook on Protalix BioTherapeutics (NYSE:PLX) with the action "Downgrade", setting a "Hold" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page. Upgrade to MarketBeat All AccessThis premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.Upgrade Now See Benefits Already have an account? Log in here. More Ratings on Protalix BioTherapeuticsDateBrokerageAction5/12/2025Wall Street ZenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngrade3/20/2025Wall Street ZenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngrade3/12/2025Wall Street ZenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgrade2/4/2025Wall Street ZenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngrade2/3/2025HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price Target1/24/2025Wall Street ZenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeMore Protalix BioTherapeutics, Inc. Ratings More Ratings from AurigaDateCompanyAction5/24/2012PDCOPatterson CompaniesReiterated Rating5/24/2012TMOThermo Fisher ScientificReiterated Rating5/24/2012HEIHeicoReiterated Rating5/24/2012STPFQSuntech PowerReiterated Rating5/23/2012TEVATeva Pharmaceutical IndustriesInitiated CoverageMore Ratings From Auriga Return to Ratings Search Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
